Johnson & Johnson (NYSE:JNJ) Trading 0% Higher – Time to Buy?

Shares of Johnson & Johnson (NYSE:JNJ) rose 0% during trading on Wednesday . The stock traded as high as $146.05 and last traded at $144.79. Approximately 1,549,967 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 7,626,000 shares. The stock had previously closed at $144.75.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on JNJ shares. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Bank of America dropped their price target on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $174.29.

Johnson & Johnson Stock Down 0.5 %

The company has a market capitalization of $353.99 billion, a PE ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock’s 50 day moving average is $148.68 and its 200 day moving average is $155.96.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the company earned $2.66 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 71.78%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Institutional investors and hedge funds have recently modified their holdings of the business. Red Door Wealth Management LLC grew its stake in Johnson & Johnson by 27.3% in the 4th quarter. Red Door Wealth Management LLC now owns 65,093 shares of the company’s stock worth $9,414,000 after buying an additional 13,962 shares in the last quarter. Madrona Financial Services LLC grew its position in Johnson & Johnson by 4.3% in the fourth quarter. Madrona Financial Services LLC now owns 2,120 shares of the company’s stock worth $307,000 after acquiring an additional 87 shares in the last quarter. Endeavor Private Wealth Inc. bought a new position in Johnson & Johnson in the fourth quarter valued at $50,000. Raleigh Capital Management Inc. raised its position in Johnson & Johnson by 48.3% during the fourth quarter. Raleigh Capital Management Inc. now owns 14,773 shares of the company’s stock valued at $2,136,000 after purchasing an additional 4,810 shares in the last quarter. Finally, Asset Planning Services Inc. LA ADV boosted its holdings in shares of Johnson & Johnson by 3.1% in the 4th quarter. Asset Planning Services Inc. LA ADV now owns 37,224 shares of the company’s stock worth $5,383,000 after purchasing an additional 1,120 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.